Akeso Starts Phase III Trial of Bispecific Immunotherapy for NSCLC
publication date: Jan 31, 2022
Hangzhou's Akeso has dosed the first patient in a Phase III trial of its bi-specific novel immuno-oncology drug, ivonescimab. It is being tested in non-squamous non-small cell lung cancer patients with an EGFR mutation who had failed an EGFR-TKI treatment. Ivonescimab, a PD-1/VEGF bi-specific antibody, will be administered along with chemotherapy. Akeso said an immunotherapy/anti-angiogenesis combination is a promising therapy because the anti-angiogenic arm normalizes tumor blood vessels, improving the tumor microenvironment for the immunotherapy. More details....
Stock Symbol: (HK: 9926)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.